In a court filing this week, the US Food and Drug Administration (FDA) stated that the review process for premarket tobacco product applications (PMTAs) for some of the most popular electronic cigarettes on the market may not be completed until December 31, 2023.
Earlier, at the 2022 Global Tobacco and Nicotine Forum (GTNF), Brian A. King, director of the Center for Tobacco Products (CTP) at the U.S. Food and Drug Administration (FDA), promised that the CTP would finish the remaining portion of 6.7 million applications by mid-2023. However, according to the latest information, the timeline for completing all application approvals will be delayed by six months.
The court initially set a deadline of September 9, 2021 for the completion of pre-market tobacco product applications (PMTAs) for electronic cigarettes. However, this deadline has now been exceeded by 16 months.
2FIRSTS will continue to follow this issue and report on it in the upcoming month as we engage in a dialogue with the FDA concerning the future of electronic cigarettes in the United States. Stay tuned for updates.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
